ChinaBio® Today Articles

Welcome to the ChinaBio® Today store. As a service to our readers, we offer access to individual articles for only $5.00 (USD) each.  Of course, a subscription is only $20/mo, so you may prefer to subscribe.  If so, click on Subscribe in the menu.

Browse


All Products

Viewing 841 - 855 of 5996 products
Ablaze Plans $100 Million Facility in Chengdu Medical City for Targeted Radiation Therapies
$5.00
Available
Zenas to Start China Trials of Thyroid Eye Disease Therapy
$5.00
Available
Sironax Closes $200 Million Round for Novel Degenerative Disease Therapies
$5.00
Available
Structure Therapeutics Closes $33 Million for Novel Small Molecule Drugs
$5.00
Available
OriCell Closes $120 Million Round for Cell Therapies and Bispecific Candidates
$5.00
Available
GluBio Completes $22 Million Funding for Protein Degradation Candidates
$5.00
Available
CSPC Pharma Out-Licenses Claudin18.2 ADC in Deal with $1 Billion in Commercial Milestones
$5.00
Available
Maxvax Completes $74 Million Series B for China Vaccine Development
$5.00
Available
Kelun-Biotech Out-Licenses Second ADC Candidate to MSD in $936 Million Deal
$5.00
Available
BridGene Closes $38.5 Million Funding from China Investors for Novel Small Molecule Targets
$5.00
Available
Legend Bio Plans to Raise $250 Million in Public Offering of Shares
$5.00
Available
HanX and Lepu Approved to Launch PD-1 mAb for Colorectal Cancer
$5.00
Available
InvestisBio Completes $296 Million IPO on the Shanghai STAR Board
$5.00
Available
Rona Therapeutics In-licenses Exclusive Global Rights to Sanofi’s siRNA Platform
$5.00
Available
WuXi Biologics and WuXi AppTec to Spend $2.8 Billion to Build Separate Singapore Facilities
$5.00
Available